Africa: Takeda Presents Analyses From Vedolizumab Data in Ulcerative Colitis At 2016 Digestive Disease Week (DDW) Annual Meeting
[PR Newswire] Osaka -Takeda Pharmaceutical Company Limited [TSE: 4502], ("Takeda") today announced the oral presentations of two data analyses: one evaluating the optimal position of vedolizumab in the ulcerative colitis (UC) treatment paradigm, and a second separate analysis assessing whether early vedolizumab trough levels were associated with subsequent drug efficacy. Findings were presented during the 2016 Digestive Disease Week (DDW) Annual Meeting in San Diego, California, and were included in a total of 13 Takeda-sponso
In this study, we aimed to describe sexual function in Puerto Rican women with IBD. METHODS: We conducted a cross-sectional study of women with IBD at the University of Puerto Rico Center for IBD. Patients were invited to anonymously complete the validated Spanish version of the Female Sexual Function Index (FSFI) questionnaire. On this 36-point scale, a score of 26.55 or less is defined as sexual dysfunction. Data were analyzed by diagnosis, presence of an ostomy, and age, using descriptive statistics, ANOVA, Student's t test, and logistic regression. RESULTS: One hundred women completed the FSFI questionnaire, wi...
The article “Characterization of Creatine Kinase Levels in Tofacitinib–Treated Patients with Ulcerative Colitis: Results from Clinical Trials”, written by Remo Panaccione, John D. Isaacs, Lea Ann Chen, Wenjin Wang, Amy Marren, Kenneth Kwok, Lisy Wang, Gary Chan and Chinyu Su, was originally published electronically on the publisher’s internet portal on 20 August 2020 without open access.
No abstract available
This study provides a framework for the application of the induced patient-derived organoids as a more comprehensive model to study human UC.
Authors: Kim JY, Lee Y, Choe BH, Kang B Abstract Background/Aims: Anti-drug antibodies (ADAs) can develop during treatment with anti-tumor necrosis factor (TNF) agents. We aimed to investigate the factors associated with immunogenicity of anti-TNF agents in pediatric patients with inflammatory bowel disease (IBD) and observe the clinical course of ADA-positive patients. Methods: Pediatric IBD patients receiving maintenance treatment with anti-TNF agents who had been tested for ADAs against infliximab (IFX) or adalimumab (ADL) were included in this crosssectional study. Factors associated with ADA positivity wer...
We aimed to compare safety and effectiveness of vedolizumab to tumor necrosis factor (TNF)-antagonist therapy in ulcerative colitis in routine practice.
Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). The efficacy and safety of tofacitinib in patients with moderate to severe UC, up to 1 year, have been reported. We investigated maintenance of efficacy in patients in remission after 52 weeks of maintenance treatment in the pivotal phase 3 study (OCTAVE Sustain); these patients received open-label, long-term treatment with tofacitinib 5 mg twice daily.
Condition: Colitis, Ulcerative Interventions: Drug: GLPG3970; Drug: Placebo Sponsor: Galapagos NV Recruiting
ConclusionA significant proportion of patients with severe colitis failing IV steroids responded to induction therapy with CT-P13. Colectomy-free survival rates were similar to previous randomized trials using originator infliximab as induction therapy in severe steroid-refractory colitis.
ConclusionPatients with IBD were often readmitted for opiate use disorder and sustained significant mortality and hospital costs. Psychiatric comorbidities, gender, and insurance status impacted the odds of readmission and represent targets for intervention.